Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP16001 PK/PD in Hepatic Impairment
NCT05747664Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Apr 2023; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05747664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747664.